Tuberous sclerosis complex: Recent advances in manifestations and therapy
Authors:
- Mari Wataya‐KanedaMWMari Wataya‐Kaneda
- Kazutoshi FujitaKFKazutoshi Fujita
- the Tuberous Sclerosis Complex Board of Osaka University HospitalTHthe Tuberous Sclerosis Complex Board of Osaka University Hospital
Open Access
- 1 July 2017
- journal article
- review article
- Published by Wiley in International Journal of Urology
- Vol. 24 (9) , 681-691
Abstract
Tuberous sclerosis complex is an autosomal dominant inherited disorder characterized by generalized involvement and variable manifestations with a birth incidence of 1:6000. In a quarter of a century, significant progress in tuberous sclerosis complex has been made. Two responsible genes, TSC1 and TSC2, which encode hamartin and tuberin, respectively, were discovered in the 1990s, and their functions were elucidated in the 2000s. Hamartin–Tuberin complex is involved in the phosphoinositide 3‐kinase–protein kinase B–mammalian target of rapamycin signal transduction pathway, and suppresses mammalian target of rapamycin complex 1 activity, which is a center for various functions. Constitutive activation of mammalian target of rapamycin complex 1 causes variable manifestations in tuberous sclerosis complex. Recently, genetic tests were launched to diagnose tuberous sclerosis complex, and mammalian target of rapamycin complex 1 inhibitors are being used to treat tuberous sclerosis complex patients. As a result of these advances, new diagnostic criteria have been established and an indispensable new treatment method; that is, “a cross‐sectional medical examination system,” a system to involve many experts for tuberous sclerosis complex diagnosis and treatments, was also created. Simultaneously, the frequency of genetic tests and advances in diagnostic technology have resulted in new views on symptoms. The numbers of tuberous sclerosis complex patients without neural symptoms are increasing, and for these patients, renal manifestations and pulmonary lymphangioleiomyomatosis have become important manifestations. New concepts of tuberous sclerosis complex‐associated neuropsychiatric disorders or perivascular epithelioid cell tumors are being created. The present review contains a summary of recent advances, significant manifestations and therapy in tuberous sclerosis complex.Keywords
This publication has 102 references indexed in Scilit:
- Trends in the Prevalence of Tuberous Sclerosis Complex Manifestations: An Epidemiological Study of 166 Japanese PatientsPLOS ONE, 2013
- Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complexNature Communications, 2012
- WIPI1 Coordinates Melanogenic Gene Transcription and Melanosome Formation via TORC1 InhibitionJournal of Biological Chemistry, 2011
- The natural history of epilepsy in tuberous sclerosis complexEpilepsia, 2010
- Molecular mechanisms of mTOR-mediated translational controlNature Reviews Molecular Cell Biology, 2009
- The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2Molecular and Cellular Biology, 2008
- BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reportsJournal of Medical Genetics, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- PEComas: the past, the present and the futureVirchows Archiv, 2007
- PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTORJournal of Clinical Investigation, 2007